Related Experiment Videos
[Clinical manifestations of infectious erythema in adults]
D Mikić1, V Marinković, P Mijusković
1Vojnomedicinska akademija, Klinika za infektivne i tropske bolesti, Beograd.
Insights
Infectious erythema, a childhood illness caused by parvovirus B19, presented with fever and rash in young adults. Antibody testing confirmed parvovirus B19 as the cause in most patients.
Area of Science:
- Virology
- Pediatrics
- Infectious Diseases
Context:
- Infectious erythema, commonly known as fifth disease, is a childhood illness.
- Parvovirus B19 is the causative agent.
- This study examines cases in young adults.
Purpose:
- To describe the clinical presentation and serological findings of parvovirus B19 infection.
- To analyze the duration of symptoms and complications.
Summary:
- 36 patients with infectious erythema (mean age 21) were treated.
- Symptoms included fever (5.2 days), maculopapular rash (6 days), and occasional polyarthralgia and mild anemia.
- IgM and IgG antibodies to parvovirus B19 were detected in 91.7% and 58.3% of patients, respectively.
Impact:
- Provides insights into the clinical spectrum of parvovirus B19 infection in young adults.
- Highlights the diagnostic utility of serological testing for parvovirus B19.
- Contributes to understanding the epidemiology of infectious erythema.
Abstract:
The infectious erythema is usually childhood disease associated with rash and caused by parvovirus B19. At the beginning of 1993., at the Clinic for infectious and tropical diseases of the Military Medical Academy 36 patients were treated for this disease, the average age 21 years. The prodromal phase of illness lasted approximately 2.9 days, the elevated temperature 5.2 days, and 17 patients had temperature above 39 degrees C. The rash was usually maculo-papullous and lasted about 6 days. Four patients had the recurrence of rash. The polyarthralgia appeared for short in six patients and in one patient lasted longer than 4 months. The mild anemia during infectious erythema was observed in 18 patients. IgM antiparvo B19 antibodies were proven in serum in 91.7%, and IgG antibodies in 58.3% of patients.